An ongoing dialogue on HIV/AIDS, infectious diseases,
July 1st, 2012
“HAART Era” Now Longer Than “Pre-HAART Era” — Can We Officially Retire “HAART”?
As I’ve shared before, I’m no fan of the term “HAART” and do everything I can to stop people from using it.
(I’m a fun guy to have at parties.)
I’m returning to this pet peeve of mine because I realized recently that we’ve passed a milestone of sorts:
- Period of no effective HIV treatment, 15 years (1981-1996)
- Period of effective HIV treatment, 16 years (1996-2012)
I came to this realization while reviewing a manuscript on an HIV-related complication. The author repeatedly (and at great length) described how this complication had changed with the “advent of HAART” (cringe) –incidence down, prognosis better, management altered. There were many comparisons between the “pre-HAART era” and the “post-HAART era”, even a separate table on the differences.
Of historical interest, yes, but hardly earth-shattering news at this point , and not of much practical use to the reader –pretty much everything changed with effective HIV treatment.
The bottom line is that HIV-related complications should be considered now only in the context of patients who are receiving, or who are about to receive, antiretroviral therapy. In other words, describing how to manage HIV-related complications without HIV treatment would be like an endocrinologist describing management of Type 1 diabetes complications without insulin.
So since HIV treatment is now the new normal — becoming more so with each passing year — let’s just call it antiretroviral therapy, and assume that it’s standard of care to give the highly active kind.
And if you want to abbreviate it, “ART” will do just fine.
Paul E. Sax, MD
Learn more about HIV and ID Observations.
Follow HIV and ID Observations Posts via Email
- Endless Recertification in Medicine — Some Thoughts About the Tests We Take
- Long-Acting Cabotegravir-Rilpivirine for People Not Taking Oral Therapy — Time to Modify Treatment Guidelines?
- My Vote for the Weirdest Antibiotic on the Planet
- Learning the Names of HIV Drugs Is Horribly Difficult — Here’s Why
- Clinical Teaching at the 99.9th Percentile: Dr. Martin (Marty) Samuels
- ID Cartoon Caption Contest (125)
- ID Cartoon Caption Contest #2 Winner — and a New Contest for the Holidays (92)
- Dear Nation — A Series of Apologies on COVID-19 (80)
- How to Induce Rage in a Doctor (77)
- IDSA’s COVID-19 Treatment Guidelines Highlight Difficulty of “Don’t Just Do Something, Stand There” (74)
- European Endocarditis Guidelines: 2023 Update
- In the Horn of Africa, Malaria Parasites Can Evade Diagnosis and Resist Treatment
- Ongoing Fungal Meningitis Outbreak Associated with Epidural Anesthesia
- Reconsidering CMV Serostatus in Hematopoietic Cell Transplant Recipients
- Missed Chances for Screening in Persons Newly Diagnosed with HIV: New York City, 2018–2022
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease MRSA PEP Policy PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster